International Journal of Antimicrobial Agents

Size: px
Start display at page:

Download "International Journal of Antimicrobial Agents"

Transcription

1 International Journal of Antimicrobial Agents 35 (2010) Contents lists available at ScienceDirect International Journal of Antimicrobial Agents journal homepage: Antimicrobial resistance among clinical isolates from the Chinese Meropenem Surveillance Study (CMSS), Hui Wang a,, Minjun Chen a,, Yuxing Ni b, Yudong Liu a, Hongli Sun a, Yunsong Yu c, Xiujuan Yu d, Yaning Mei e, Min Liu f, Ziyong Sun g, Yunzhuo Chu h, Zhidong Hu i, Xinhong Huang j a Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, No. 1 Shuaifuyuan, Wangfujing, Beijing , China b Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai , China c First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou , China d Qi Lu Hospital of Shandong University, Jinan , China e The First Affiliated Hospital of Nanjing Medical University, Nanjing , China f The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou , China g Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan , China h The First Hospital of China Medical University, Shenyang , China i General Hospital, Tianjin Medical University, Tianjin , China j Fujian Medical University Union Hospital, Fuzhou , China article info abstract Article history: Received 27 September 2009 Accepted 17 November 2009 Keywords: Antibiotic surveillance Gram-negative bacilli Resistance Meropenem The Chinese Meropenem Surveillance Study (CMSS) programme was initiated in 2003 with the aim of monitoring the antimicrobial activity of broad-spectrum agents against nosocomial Gram-negative bacilli in China. From 2003 to 2008, a total of 3892 isolates were collected from 10 teaching hospitals. The minimum inhibitory concentrations (MICs) of 11 antimicrobial agents were determined by the agar dilution method. During the study period, a marked decrease in the susceptibility of Acinetobacter spp. to meropenem and imipenem was noticed, from 94.6% to 60.7% and from 92.5% to 62.1%, respectively. However, for Pseudomonas aeruginosa the susceptibility was relatively stable, with susceptibility rates of 86.2% to 76.0% for meropenem and 74.8% to 70.5% for imipenem. Meropenem and imipenem exhibited the highest activities against enterobacterial organisms, with ranges of MIC 90 values (MIC for 90% of the organisms) from mg/l to 0.25 mg/l and 0.25 to 4 mg/l, respectively. Except for Acinetobacter spp., the next most active agent against the majority of isolates was amikacin, with susceptibility ranging from 78.8% to 93.3%, followed by piperacillin/tazobactam (73.7% to 98.2%), cefoperazone/sulbactam (63.9% to 99.1%), cefepime (67.0% to 95.4%) and ceftazidime (54.5% to 93.3%). The percentage of isolates positive for extended-spectrum -lactamases among Escherichia coli, Klebsiella spp. and Proteus mirabilis ranged from 50.9% to 66.7%, 25.4% to 42.4% and 8.9% to 24.2%, respectively. These CMSS results have demonstrated increasing resistance of Acinetobacter spp. to carbapenems, resulting from the spread of highly resistant clones. Continued surveillance studies, including CMSS, as well as potent measures for controlling the spread of resistant clones are required Elsevier B.V. and the International Society of Chemotherapy. All rights reserved. 1. Introduction The increase in antimicrobial resistance among Gram-negative bacilli is a significant and increasing problem worldwide [1 4]. Antimicrobial surveillance programmes that offer extensive information on patterns of bacterial resistance in different geographical regions and different periods play a pivotal role in the fight against increasing bacterial resistance and contribute to the selection of the most appropriate antimicrobial agents in clinical practice [5]. Corresponding authors. Tel.: addresses: wh bj@tom.com (H. Wang), chmj1933@hotmail.com (M. Chen). The Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme, which was initiated in 1997, is a unique global multicentre longitudinal surveillance study that has provided significant longevity and value [6]. However, this programme has mainly focused on North and South America and Europe, with few data having been reported from other regions, particularly mainland China. To address this gap, the Chinese Meropenem Surveillance Study (CMSS) programme was initiated in The CMSS is a multicentre national surveillance programme of the activity of meropenem and comparator agents that includes 10 teaching hospitals from 10 major cities throughout China. In the present report from CMSS, minimum inhibitory concentrations (MICs) are presented, and susceptibility and resistance rates are interpreted among /$ see front matter 2009 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved. doi: /j.ijantimicag

2 228 H. Wang et al. / International Journal of Antimicrobial Agents 35 (2010) Table 1 Overall in vitro susceptibility to 11 antimicrobial agents of clinical Gram-negative isolates in China, Organism Antimicrobial agent MIC Susceptibility a Range MIC 50 MIC 90 %S %R Escherichia coli (n = 590) Pseudomonas aeruginosa (n = 548) Klebsiella spp. (n = 531) Enterobacter spp. (n = 522) Acinetobacter spp. (n = 486) Meropenem to Imipenem to Cefoxitin to Cefotaxime to Ceftriaxone to Ceftazidime to Cefepime to CSL to TZP 0.25 to Amikacin to Ciprofloxacin to Meropenem to Imipenem to Cefoxitin to Cefotaxime to Ceftriaxone to Ceftazidime to Cefepime to CSL to TZP 0.5 to Amikacin to Ciprofloxacin to Meropenem to Imipenem to Cefoxitin 1 to Cefotaxime to Ceftriaxone to Ceftazidime to Cefepime to CSL to TZP 0.25 to Amikacin to Ciprofloxacin to Meropenem to Imipenem to Cefoxitin to Cefotaxime to Ceftriaxone to Ceftazidime to Cefepime to CSL to TZP to Amikacin to Ciprofloxacin to Meropenem to Imipenem to Cefoxitin to Cefotaxime to Ceftriaxone to Ceftazidime to Cefepime to CSL to TZP to Amikacin to Ciprofloxacin to Proteus spp. (n = 331) Meropenem to Imipenem to Cefoxitin to Cefotaxime to Ceftriaxone to > Ceftazidime to Cefepime to CSL to TZP to Amikacin to Ciprofloxacin to

3 H. Wang et al. / International Journal of Antimicrobial Agents 35 (2010) Table 1 (Continued) Organism Antimicrobial agent MIC Susceptibility a Range MIC 50 MIC 90 %S %R Citrobacter spp. (n = 254) Meropenem to Imipenem to Cefoxitin 1 to Cefotaxime to Ceftriaxone to Ceftazidime to Cefepime to CSL to TZP 0.25 to Amikacin to Ciprofloxacin to Serratia spp. (n = 195) Meropenem to Imipenem to Cefoxitin to Cefotaxime to Ceftriaxone to Ceftazidime to Cefepime to CSL to TZP to Amikacin to Ciprofloxacin to MIC, minimum inhibitory concentration; MIC 50/90, MIC for 50% and 90% of the organisms, respectively; %S, percent susceptible; %R, percent resistant; CSL, cefoperazone/sulbactam; TZP, piperacillin/tazobactam. a According to Clinical and Laboratory Standards Institute guidelines [8]. Gram-negative bacteria collected in China between 2003 and Materials and methods 2.1. Bacterial isolates In 2003, 2004, 2006 and 2008, 10 teaching hospitals from 10 central cities throughout China participated in the CMSS programme. The cities are distributed in southern China (including Shanghai, Hangzhou, Wuhan, Nanjing, Guangzhou and Fuzhou) and northern China (including Beijing, Tianjin, Shenyang and Jinan). From September to December of each surveillance year, each centre collected 100 consecutive, non-repeat clinical isolates of Gram-negative bacilli and sent them to the central laboratory (Clinical Microbiology, Peking Union Medical College Hospital, Beijing, China). Owing to its intrinsic resistance to carbapenems, Stenotrophomonas maltophilia was excluded. A total of 3892 non-repeat isolates was collected. Isolates were identified at the local laboratory, and again at the central laboratory for confirmation, using colonial morphology, routine biochemical tests and/or the Vitek system identification cards (biomérieux, Hazelwood, MO), as required. All isolates were stored at 80 C until MICs were measured Antimicrobial susceptibility testing The MICs of 11 antibiotics were determined for each isolate by agar dilution at the central laboratory according to Clinical and Laboratory Standards Institute (CLSI) guidelines [7]. The antimicrobials tested included meropenem (Sumitomo Pharmaceuticals Co., Osaka, Japan), imipenem (Sigma Chemical Co., St Louis, MO), ceftazidime (Sigma), cefotaxime (Sigma), ceftriaxone (Sigma), cefepime (Sigma), piperacillin/tazobactam (TZP) (Wyeth Pharmaceuticals, Collegeville, PA), cefoperazone/sulbactam (CSL) (2:1) (Sigma), cefotaxime/clavulanic acid (Sigma), cefoxitin (Sigma), amikacin (Sigma), ceftazidime/clavulanic acid (Sigma) and ciprofloxacin (Bayer AG, Leverkusen, Germany). The procedures for each set of tests were validated by determining the MICs for reference strains (Pseudomonas aeruginosa ATCC 27853, Escherichia coli ATCC and E. coli ATCC 35218), as recommended by CLSI standards. The results were interpreted according to CLSI breakpoints [8]. The cefoperazone MIC breakpoint was used for CSL as no breakpoint is available for this combination. The CLSI extended-spectrum -lactamase (ESBL) screening criterion (MIC 2 mg/l for either ceftazidime or cefotaxime) was applied to E. coli, Klebsiella spp. and Proteus mirabilis. ESBL production was confirmed using two pairs of drug combinations, cefotaxime/cefotaxime + clavulanic acid and ceftazidime/ceftazidime + clavulanic acid. An isolate was deemed to be ESBL-positive if the addition of clavulanic acid reduced the MIC of either of the -lactam agents by three-fold or more. Escherichia coli ATCC and Klebsiella pneumoniae ATCC were used as controls for the confirmatory ESBL test Data analysis For each isolate, the local laboratory recorded associated clinical information, including specimen type, collection date and medical specialty, on a standard case report form. All data, including MICs, were analysed by WHONET 5.4 software at the central laboratory. The prevalence of multidrug resistance was investigated among isolates of P. aeruginosa and Acinetobacter spp. Isolates of those species resistant to three or four antimicrobials among ceftazidime, meropenem or imipenem, amikacin and ciprofloxacin were considered to be multidrug-resistant (MDR). In the same species, pandrug resistance was defined as those isolates that were resistant to every antibacterial agent tested Repetitive extragenic palindromic sequence-based polymerase chain reaction (REP-PCR) typing REP-PCR using a method described previously [9] was employed to investigate epidemiological relationships among meropenemresistant Acinetobacter spp. isolated in The resulting patterns were examined visually. Identical profiles or highly similar profiles (up to two bands difference) were interpreted as indicating clonally identical or very closely related isolates [9].

4 Table 2 Cumulative percentage of each organism inhibited at different minimum inhibitory concentrations (MICs) by five antimicrobial agents. Organism Agent Cumulative percentage of isolates inhibited at MIC : Pseudomonas aeruginosa (n = 548) Acinetobacter baumannii (n = 454) MEM IPM CAZ TZP CIP MEM IPM CAZ TZP CIP Escherichia coli (n = 590) MEM IPM CAZ TZP CIP Klebsiella spp. (n = 531) MEM IPM CAZ TZP CIP MEM, meropenem; IPM, imipenem; CAZ, ceftazidime; TZP, piperacillin/tazobactam; CIP, ciprofloxacin. 230 H. Wang et al. / International Journal of Antimicrobial Agents 35 (2010)

5 Table 3 Change in MIC 50 and MIC 90 values of each antimicrobial agent against Pseudomonas aeruginosa and Acinetobacter spp. Organism %S MIC 50 MIC 90 MIC range %S MIC 50 MIC 90 MIC range %S MIC 50 MIC 90 MIC range %S MIC 50 MIC 90 MIC Range Pseudomonas aeruginosa MEM to to to to IPM to to to to CAZ to to to to FEP to to to to CSL to to to to TZP to to to to AMK to to to to CIP to to to to Acinetobacter spp. MEM to to to to IPM to to to to CAZ to to to to FEP to to to to 256 CSL to to to to TZP to to to to AMK to to to to CIP to to to to MIC 50/90, MIC for 50% and 90% of the organisms, respectively; MEM, meropenem; IPM, imipenem; CAZ, ceftazidime; FEP, cefepime; CSL, cefoperazone/sulbactam, TZP, piperacillin/tazobactam; AMK, amikacin CIP, ciprofloxacin. H. Wang et al. / International Journal of Antimicrobial Agents 35 (2010)

6 232 H. Wang et al. / International Journal of Antimicrobial Agents 35 (2010) Table 4 Prevalence by year of multidrug resistance and pandrug resistance in Pseudomonas aeruginosa and Acinetobacter baumannii, and proportion of extended-spectrum -lactamase (ESBL)-producing Enterobacteriaceae. Organism % (no. of isolates) a MDR P. aeruginosa b 11.3 (14/123) 14.9 (18/121) 13.3 (21/158) 17.1 (25/146) PDR P. aeruginosa c 2.4 (3/123) 2.5 (3/121) 5.1 (8/158) 7.5 (11/146) MDR A. baumannii 36.4 (32/88) 47.5 (47/99) 49.6 (69/139) 59.4 (76/) PDR A. baumannii 1.1 (1/88) 3.0 (3/99) 6.5 (9/139) 14.1 (18/) ESBL-producing Escherichia coli 55.8 (87/156) 50.9 (82/161) 66.7 (88/132) 61.0 (86/141) ESBL-producing Klebsiella spp (56/132) 25.4 (32/126) 35.9 (47/131) 36.6 (52/142) ESBL-producing Proteus mirabilis 13.0 (6/46) 8.9 (4/45) 24.0 (12/50) 24.2 (16/66) MDR, multidrug-resistant; PDR, pandrug-resistant. a Significant differences were observed between the years 2003 and 2008 for MDR A. baumannii ( 2 = 11.03, P < 0.01) and for PDR A. baumannii ( 2 = 10.98, P < 0.01), but not for other organisms. b Multidrug resistance for Gram-negative bacilli was defined as resistance to three or more of the following antimicrobials: ceftazidime; meropenem or imipenem; amikacin; and ciprofloxacin. c Pandrug-resistant isolates were defined as those that were resistant to every antibacterial agent tested Statistical analysis Fisher s exact test or 2 test was used to analyse qualitative variables, as appropriate. A P-value of <0.05 was considered statistically significant. 3. Results 3.1. Distribution of isolates The majority of isolates were recovered from respiratory tract specimens (1980/3892; 50.9%), followed by urinary tract (549/3892; 14.1%) and blood (349/3892; 9.0%); the remaining isolates were obtained from secretions (219/3892; 5.6%), pus (203/3892; 5.2%), drainage (148/3892; 3.8%), bile (115/3892; 3.0%), surgical wounds (81/3892; 2.1%) and other body sites. The most common organisms, in order of frequency, were E. coli (590/3892; 15.2%), P. aeruginosa (548/3892; 14.1%), Klebsiella spp. (531/3892; 13.6%), Enterobacter spp. (522/3892; 13.4%), Acinetobacter spp. (486/3892; 12.5%), Proteus spp. (331/3892; 8.5%), Citrobacter spp. (254/3892; 6.5%) and Serratia spp. (195/3892; 5.0%) Antimicrobial activity against major organisms from 2003 to 2008 Antimicrobial susceptibility data for the major organisms are presented in Table 1. Meropenem and imipenem were consistently the most active agents against most of the isolates [>95% susceptible by CLSI criteria, except among P. aeruginosa and Acinetobacter spp., which exhibited lower frequencies of susceptible isolates ( % and %, respectively)]. Except for Acinetobacter spp., the next most active agent was amikacin, with susceptibility from 78.8% to 93.3%, followed by TZP ( %), CSL ( %), cefepime ( %) and ceftazidime ( %). Cefoxitin, in general, was observed to have the highest resistance rates among all of the agents tested. Proteus spp. exhibited high rates of susceptibility to most agents (>85%, except for ciprofloxacin and ceftriaxone), with a similar pattern observed in Serratia spp. (>75%, except for cefoxitin). Among Acinetobacter spp. isolates, only 40.4% were susceptible to ciprofloxacin, 47.5% to TZP and 48.5% to amikacin. In contrast, among P. aeruginosa isolates the susceptible percentages for the above three agents were 67.9%, 73.7% and 78.8%, respectively. TZP, amikacin and ceftazidime remained active against E. coli, with susceptible rates >80%. Table 2 lists the cumulative percent inhibition of four organism groups at different MICs by five antimicrobial agents. More than 95% of E. coli and Klebsiella spp. were inhibited by meropenem or imipenem at a concentration of 1 mg/l, and >80% of isolates were inhibited by TZP or ceftazidime at a concentration of 16 mg/l. However, only 22.2% of E. coli and 57.9% of Klebsiella spp. were inhibited by ciprofloxacin at 1 mg/l, which is the susceptible breakpoint. Nearly 70% of the E. coli isolates that were resistant to ciprofloxacin displayed a ciprofloxacin MIC of 64 mg/l. Among P. aeruginosa and Acinetobacter spp., >70% of isolates were inhibited by meropenem or imipenem concentrations of 4 mg/l. Meropenem exhibited a slightly higher susceptible rate than imipenem in P. aeruginosa (80.5% vs. 71.5%). Similar to the ciprofloxacin pattern in E. coli, nearly 70% of ciprofloxacin-resistant Acinetobacter spp. displayed a ciprofloxacin MIC of 64 mg/l; however, for P. aeruginosa, ca. 70% of isolates displayed an MIC of 1 mg/l and 99.6% isolates were inhibited by ciprofloxacin at 64 mg/l Changes in antimicrobial susceptibility of the five most common organisms Pseudomonas aeruginosa and Acinetobacter spp. In general, susceptibility profiles of P. aeruginosa for most agents remained relatively stable over the course of the study. Meropenem, imipenem, TZP and amikacin maintained high activity against P. aeruginosa, with >70% of isolates being susceptible over the study period. Acinetobacter baumannii accounted for 93.4% of Acinetobacter spp. isolates (454/486). In contrast to the relatively stable susceptibility patterns for P. aeruginosa, a decline in susceptibility to meropenem and imipenem was observed in Acinetobacter spp. Specifically, susceptibility to meropenem decreased significantly from 94.6% in 2003 to 60.7% in 2008 ( 2 = 33.93, P < 0.01). Over the same period, the MIC 50 and MIC 90 values (MIC for 50% and 90% of the organisms, respectively) increased from 0.5 mg/l and 2 mg/l, respectively, to 1 mg/l and 64 mg/l. In the case of imipenem, the susceptibility rate declined from 92.5% to 62.1% ( 2 = 27.32, P < 0.01) and the MIC 50 and MIC 90 increased from 0.5 mg/l and 2 mg/l, respectively, to 1 mg/l and 64 mg/l (Table 3). Increases in rates of resistance were also revealed for other agents, such as CSL, TZP and amikacin. The prevalence of multidrug resistance in P. aeruginosa and A. baumannii from 2003 to 2008 is presented in Table 4. The prevalence of multidrug resistance increased in both species over the period of the study and in the case of A. baumannii this increase was statistically significant ( 2 = 11.03, P < 0.01). A similar trend was also observed in the prevalence of A. baumannii isolates resistant to all the tested agents (pandrug resistance), which increased from 1.1% to 14.1% ( 2 = 10.98, P < 0.01). Pan-resistance also occurred in

7 H. Wang et al. / International Journal of Antimicrobial Agents 35 (2010) P. aeruginosa over the study time period, but this did not reach the level of significance. All 55 meropenem-resistant Acinetobacter spp. isolated in 2008 were investigated by REP-PCR and five REP-PCR types were identified. The most prevalent clone was REP-PCR type 1, which accounted for 61.5% of all isolates and was distributed across five hospitals. The next most common clone was type 3 (15.4%) Escherichia coli, Klebsiella spp. and Enterobacter spp. During the 6-year study period, susceptibility profiles for E. coli and Klebsiella spp. remained stable for all agents (data not shown). In general, meropenem and imipenem were the most active agents against E. coli and Klebsiella spp. From 2003 to 2008, % of E. coli and % of Klebsiella spp. were susceptible to carbapenems. However, the MIC 50 and MIC 90 of imipenem against the combined E. coli isolates and the combined Klebsiella spp. isolates were four- to eight-fold higher than those of meropenem (Table 1). TZP was the second most active agent, against which % of E. coli and % of Klebsiella spp. isolates were susceptible. Amikacin, CSL, cefepime and ceftazidime also showed stable activity against these species (susceptibility remaining >70%). However, the percent susceptibility of E. coli to cefotaxime, ceftriaxone and ciprofloxacin was relatively low. Compared with E. coli, Klebsiella spp. were more susceptible to cefotaxime and ciprofloxacin. The percent susceptibilities to ceftazidime in E. coli and Klebsiella spp. were much higher than to cefotaxime and ceftriaxone. The frequencies of ESBL phenotypes in E. coli, Klebsiella spp. and P. mirabilis were %, % and %, respectively (Table 4). An ESBL phenotype was more frequently observed in E. coli than in Klebsiella spp. or P. mirabilis. The ESBL prevalence in these species varied from year to year but without any discernible trend to increase or decrease over time. Antimicrobial resistance in the combined Enterobacter spp. was higher than in E. coli and Klebsiella spp. (Table 1). Meropenem and imipenem retained excellent activity against Enterobacter spp. (>99% of isolates susceptible). Amikacin was the second most active agent (83.9% susceptible), followed by cefepime, TZP and CSL (Table 1). 4. Discussion The antimicrobial susceptibilities of Gram-negative bacteria in China from 2003 to 2008 remained relatively stable for many organisms. However, the overall rates of resistance in the majority of the organisms had increased compared with rates in a previous time period [10]. During the 6-year period, meropenem and imipenem continued to show potent and consistent activity against Gramnegative bacteria, including ESBL-producing organisms. With the exception of Acinetobacter spp. and P. aeruginosa, meropenem and imipenem MIC 50 and MIC 90 values remained stable, i.e. no MIC creep was observed. This finding is consistent with the results of other studies undertaken in Europe and the USA [11,12]. The most surprising finding in this study was the rather dramatic decrease in the percent of Acinetobacter spp. susceptible to meropenem or imipenem during the study period. This decrease was common across many of the cities surveyed, indicating that resistance of Acinetobacter spp. to meropenem and imipenem has become a widespread and serious problem in China. Clearly, prevention and reversal of this trend is a key public health need. Note that the trend was not confined to the carbapenems, as percent susceptibilities to CSL, TZP, amikacin and ciprofloxacin in Acinetobacter spp. decreased by 15 25% compared with a previous study [10]. The REP-PCR data for Acinetobacter spp. isolated in 2008 indicated that clonal spread was the main reason for the decrease in percent susceptible. In China, clones carrying the bla OXA-23 carbapenemase gene have previously been shown to account for high carbapenem resistance [13,14]. Thus, early recognition of the presence of carbapenem-resistant Acinetobacter spp. clones is necessary in order to prevent their spread within the hospital environment and thus eventually decrease the overall resistant rates. Compared with Acinetobacter spp., rates of resistance in P. aeruginosa were relatively stable. Amikacin, TZP and ceftazidime continued to be effective agents, but susceptibilities to TZP and CSL were ca. 10% lower than previously [10]. Unlike the decreasing susceptibility to ciprofloxacin in Acinetobacter spp., the percent susceptibility to ciprofloxacin in P. aeruginosa was stable. The rates of susceptibility in P. aeruginosa presented here are much lower than those in studies in other regions of the world. For example, in Europe the percent susceptibility to TZP in P. aeruginosa was recently reported to be 86.8% [11], in the USA it was 86.6% [12] and in Canada it was 90% [15]. Similar differences occurred with other antibacterial agents. An underlying serious problem that we have observed is a continuous increase in MDR isolates both of Acinetobacter spp. and P. aeruginosa. In this study, MDR isolates increased annually. Indeed, in 2008 the multidrug resistance rate among Acinetobacter spp. was 51% of isolates, much higher than the rate in other countries. Although carbapenems remain one of the choices for infections with Acinetobacter and P. aeruginosa, the continuous increase in MDR organisms will result in more complicated treatment challenges and increased healthcare burdens. Similar to a previous report [10], rates of resistance in E. coli and Klebsiella spp. remained stable, but with a high percentage of ESBL-producing isolates (Table 4). Increasing frequencies of ESBLproducing Enterobacteriaceae have become a challenging problem worldwide, occurring in Europe and the USA, but at lower percentages than observed in our study [11,12,15 17]. The high percentage of ESBL in China may be a consequence of the selective pressure of cefotaxime and ceftriaxone, which have been widely and predominantly used in Chinese hospitals in recent years. The results of this study would undermine the rationale for the use of extendedspectrum cephalosporins or penicillins as empirical therapy for severe infections caused by Gram-negative pathogens in China owing to the high prevalence of ESBL. Compared with a previous study [10], the consistent downward trend in ciprofloxacin activity against E. coli is also a severe concern in China. Now only ca. 20% of E. coli isolates are susceptible to ciprofloxacin, which indicates that ciprofloxacin would not be suitable for the treatment of E. coli infections, especially in the intensive care unit. Decreased activity of ciprofloxacin has also been reported in many other countries [11,12,15 17]. For example, a 12-year study in the USA indicated that the rate of ciprofloxacin resistance in E. coli increased from 0.9% in 1993 to 17.3% in 2004 [11]. The molecular mechanisms of fluoroquinolone resistance in Enterobacteriaceae in China include multiple substitutions in the gyra and parc genes as well as the plasmid-mediated quinolone-resistance genes qnr and aac(6 )-Ib-cr [18]. In conclusion, the susceptibility profiles for many organisms have remained constant over the past 6 years, but a sharp decrease in the activity of meropenem or imipenem against Acinetobacter spp. has been observed. The information gathered in this study can be used in preparing evidence-based guidelines for treatment, especially empirical treatment, of bacterial infections in China. Moreover, it is clear that clonal spread of MDR Acinetobacter spp. and P. aeruginosa must be controlled as a serious public health issue. Acknowledgment Editorial and style assistance from Dr Wright W. Nichols is acknowledged.

8 234 H. Wang et al. / International Journal of Antimicrobial Agents 35 (2010) Funding: The CMSS project was funded by a research grant from Sumitomo Pharmaceuticals (Suzhou) Co., Ltd. It was partially supported by the National Natural Science Foundation of China (grant ). Competing interests: None declared. Ethical approval: Not required. References [1] Paterson DL. Resistance in Gram-negative bacteria: Enterobacteriaceae. Am J Infect Control 2006;34(5 Suppl. 1):S20 8 [Discussion S64 73]. [2] Peleg AY, Paterson DL. Multidrug-resistant Acinetobacter: a threat to the antibiotic era. Intern Med J 2006;36: [3] Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2002;34: [4] Livermore DM, Woodford N. The -lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. Trends Microbiol 2006;14: [5] Felmingham D. The need for antimicrobial resistance surveillance. J Antimicrob Chemother 2002;50(Suppl. S 1):1 7. [6] Jones RN, Mendes C, Turner PJ, Masterton R. An overview of the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program: Diagn Microbiol Infect Dis 2005;53: [7] National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 6th ed. Document M7-A6. Wayne, PA: NCCLS; [8] Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 18th ed. Document M100-S18. Wayne, PA: CLSI; [9] Snelling AM, Gerner-Smidt P, Hawkey PM, Heritage J, Parnell P, Porter C, et al. Validation of use of whole-cell repetitive extragenic palindromic sequence-based PCR (REP-PCR) for typing strains belonging to the Acinetobacter calcoaceticus Acinetobacter baumannii complex and application of the method to the investigation of a hospital outbreak. J Clin Microbiol 1996;34: [10] Wang H, Chen M; China Nosocomial Pathogens Resistance Surveillance Study Group. Surveillance for antimicrobial resistance among clinical isolates of Gram-negative bacteria from intensive care unit patients in China, 1996 to Diagn Microbiol Infect Dis 2005;51: [11] Nørskov-Lauritsen N, Marchandin H, Dowzicky MJ. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe ( ). Int J Antimicrob Agents 2009;34: [12] Lockhart SR, Abramson MA, Beekmann SE, Gallagher G, Riedel S, Diekema DJ, et al. Antimicrobial resistance among Gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and J Clin Microbiol 2007;45: [13] Wang H, Guo P, Sun H, Wang H, Yang Q, Chen M, et al. Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals. Antimicrob Agents Chemother 2007;51: [14] Zhou H, Yang Q, Yu YS, Wei ZQ, Li LJ. Clonal spread of imipenem-resistant Acinetobacter baumannii among different cities of China. J Clin Microbiol 2007;45: [15] Zhanel GG, DeCorby M, Laing N, Weshnoweski B, Vashisht R, Tailor F, et al. Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, Antimicrob Agents Chemother 2008;52: [16] Jones RN, Kirby JT, Rhomberg PR. Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance. Diagn Microbiol Infect Dis 2008;61: [17] Turner PJ. MYSTIC Europe 2007: activity of meropenem and other broadspectrum agents against nosocomial isolates. Diagn Microbiol Infect Dis 2009;63: [18] Yang H, Chen H, Yang Q, Chen M, Wang H. High prevalence of plasmidmediated quinolone resistance genes qnr and aac(6 )-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. Antimicrob Agents Chemother 2008;52:

ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat

ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat Hicham Ezzat Professor of Microbiology and Immunology Cairo University Introduction 1 Since the 1980s there have been dramatic

More information

Defining Extended Spectrum b-lactamases: Implications of Minimum Inhibitory Concentration- Based Screening Versus Clavulanate Confirmation Testing

Defining Extended Spectrum b-lactamases: Implications of Minimum Inhibitory Concentration- Based Screening Versus Clavulanate Confirmation Testing Infect Dis Ther (2015) 4:513 518 DOI 10.1007/s40121-015-0094-6 BRIEF REPORT Defining Extended Spectrum b-lactamases: Implications of Minimum Inhibitory Concentration- Based Screening Versus Clavulanate

More information

ESBL- and carbapenemase-producing microorganisms; state of the art. Laurent POIREL

ESBL- and carbapenemase-producing microorganisms; state of the art. Laurent POIREL ESBL- and carbapenemase-producing microorganisms; state of the art Laurent POIREL Medical and Molecular Microbiology Unit Dept of Medicine University of Fribourg Switzerland INSERM U914 «Emerging Resistance

More information

Received: February 29, 2008 Revised: July 22, 2008 Accepted: August 4, 2008

Received: February 29, 2008 Revised: July 22, 2008 Accepted: August 4, 2008 J Microbiol Immunol Infect. 29;42:317-323 In vitro susceptibilities of aerobic and facultative anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections at a medical center

More information

Intrinsic, implied and default resistance

Intrinsic, implied and default resistance Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been

More information

Original Article. Ratri Hortiwakul, M.Sc.*, Pantip Chayakul, M.D.*, Natnicha Ingviya, B.Sc.**

Original Article. Ratri Hortiwakul, M.Sc.*, Pantip Chayakul, M.D.*, Natnicha Ingviya, B.Sc.** Original Article In Vitro Activity of Cefminox and Other β-lactam Antibiotics Against Clinical Isolates of Extended- Spectrum-β-lactamase-Producing Klebsiella pneumoniae and Escherichia coli Ratri Hortiwakul,

More information

2015 Antimicrobial Susceptibility Report

2015 Antimicrobial Susceptibility Report Gram negative Sepsis Outcome Programme (GNSOP) 2015 Antimicrobial Susceptibility Report Prepared by A/Professor Thomas Gottlieb Concord Hospital Sydney Jan Bell The University of Adelaide Adelaide On behalf

More information

Mili Rani Saha and Sanya Tahmina Jhora. Department of Microbiology, Sir Salimullah Medical College, Mitford, Dhaka, Bangladesh

Mili Rani Saha and Sanya Tahmina Jhora. Department of Microbiology, Sir Salimullah Medical College, Mitford, Dhaka, Bangladesh Detection of extended spectrum beta-lactamase producing Gram-negative organisms: hospital prevalence and comparison of double disc synergy and E-test methods Mili Rani Saha and Sanya Tahmina Jhora Original

More information

RETROSPECTIVE STUDY OF GRAM NEGATIVE BACILLI ISOLATES AMONG DIFFERENT CLINICAL SAMPLES FROM A DIAGNOSTIC CENTER OF KANPUR

RETROSPECTIVE STUDY OF GRAM NEGATIVE BACILLI ISOLATES AMONG DIFFERENT CLINICAL SAMPLES FROM A DIAGNOSTIC CENTER OF KANPUR Original article RETROSPECTIVE STUDY OF GRAM NEGATIVE BACILLI ISOLATES AMONG DIFFERENT CLINICAL SAMPLES FROM A DIAGNOSTIC CENTER OF KANPUR R.Sujatha 1,Nidhi Pal 2, Deepak S 3 1. Professor & Head, Department

More information

Available online at ISSN No:

Available online at  ISSN No: Available online at www.ijmrhs.com ISSN No: 2319-5886 International Journal of Medical Research & Health Sciences, 2017, 6(4): 36-42 Comparative Evaluation of In-Vitro Doripenem Susceptibility with Other

More information

Michael Hombach*, Guido V. Bloemberg and Erik C. Böttger

Michael Hombach*, Guido V. Bloemberg and Erik C. Böttger J Antimicrob Chemother 2012; 67: 622 632 doi:10.1093/jac/dkr524 Advance Access publication 13 December 2011 Effects of clinical breakpoint changes in CLSI guidelines 2010/2011 and EUCAST guidelines 2011

More information

2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine

2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine 2012 ANTIBIOGRAM Central Zone Former DTHR Sites Department of Pathology and Laboratory Medicine Medically Relevant Pathogens Based on Gram Morphology Gram-negative Bacilli Lactose Fermenters Non-lactose

More information

International Journal of Pharma and Bio Sciences ANTIMICROBIAL SUSCEPTIBILITY PATTERN OF ESBL PRODUCING GRAM NEGATIVE BACILLI ABSTRACT

International Journal of Pharma and Bio Sciences ANTIMICROBIAL SUSCEPTIBILITY PATTERN OF ESBL PRODUCING GRAM NEGATIVE BACILLI ABSTRACT Research Article Microbiology International Journal of Pharma and Bio Sciences ISSN 0975-6299 ANTIMICROBIAL SUSCEPTIBILITY PATTERN OF ESBL PRODUCING GRAM NEGATIVE BACILLI * PRABHAKAR C MAILAPUR, DEEPA

More information

Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC

Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC 11/20/2014 1 To describe carbapenem-resistant Enterobacteriaceae. To identify laboratory detection standards for carbapenem-resistant

More information

DR. MICHAEL A. BORG DIRECTOR OF INFECTION PREVENTION & CONTROL MATER DEI HOSPITAL - MALTA

DR. MICHAEL A. BORG DIRECTOR OF INFECTION PREVENTION & CONTROL MATER DEI HOSPITAL - MALTA DR. MICHAEL A. BORG DIRECTOR OF INFECTION PREVENTION & CONTROL MATER DEI HOSPITAL - MALTA The good old days The dread (of) infections that used to rage through the whole communities is muted Their retreat

More information

Update on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia. Po-Ren Hsueh. National Taiwan University Hospital

Update on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia. Po-Ren Hsueh. National Taiwan University Hospital Update on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia Po-Ren Hsueh National Taiwan University Hospital Ventilator-associated Pneumonia Microbiological Report Sputum from a

More information

Int.J.Curr.Microbiol.App.Sci (2017) 6(3):

Int.J.Curr.Microbiol.App.Sci (2017) 6(3): International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 3 (2017) pp. 891-895 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.603.104

More information

Prevalence of Metallo-Beta-Lactamase Producing Pseudomonas aeruginosa and its antibiogram in a tertiary care centre

Prevalence of Metallo-Beta-Lactamase Producing Pseudomonas aeruginosa and its antibiogram in a tertiary care centre International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 4 Number 9 (2015) pp. 952-956 http://www.ijcmas.com Original Research Article Prevalence of Metallo-Beta-Lactamase

More information

EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING

EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING CHN61: EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING 1.1 Introduction A common mechanism of bacterial resistance to beta-lactam antibiotics is the production

More information

Comparison of Antibiotic Resistance and Sensitivity with Reference to Ages of Elders

Comparison of Antibiotic Resistance and Sensitivity with Reference to Ages of Elders Daffodil International University Institutional Repository DIU Journal of Science and Technology Volume 10, Issue 1-2, July 2015 2016-06-16 Comparison of Antibiotic Resistance and Sensitivity with Reference

More information

Yang et al. BMC Infectious Diseases (2017) 17:192 DOI /s x

Yang et al. BMC Infectious Diseases (2017) 17:192 DOI /s x Yang et al. BMC Infectious Diseases (2017) 17:192 DOI 10.1186/s12879-017-2296-x RESEARCH ARTICLE Open Access Antimicrobial susceptibilities of aerobic and facultative gram-negative bacilli isolated from

More information

ETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae

ETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae ETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae Thomas Durand-Réville 02 June 2017 - ASM Microbe 2017 (Session #113) Disclosures Thomas Durand-Réville: Full-time Employee; Self;

More information

Antimicrobial Cycling. Donald E Low University of Toronto

Antimicrobial Cycling. Donald E Low University of Toronto Antimicrobial Cycling Donald E Low University of Toronto Bad Bugs, No Drugs 1 The Antimicrobial Availability Task Force of the IDSA 1 identified as particularly problematic pathogens A. baumannii and

More information

Antimicrobial Susceptibility Testing: Advanced Course

Antimicrobial Susceptibility Testing: Advanced Course Antimicrobial Susceptibility Testing: Advanced Course Cascade Reporting Cascade Reporting I. Selecting Antimicrobial Agents for Testing and Reporting Selection of the most appropriate antimicrobials to

More information

Surveillance of Antimicrobial Resistance among Bacterial Pathogens Isolated from Hospitalized Patients at Chiang Mai University Hospital,

Surveillance of Antimicrobial Resistance among Bacterial Pathogens Isolated from Hospitalized Patients at Chiang Mai University Hospital, Original Article Vol. 28 No. 1 Surveillance of Antimicrobial Resistance:- Chaiwarith R, et al. 3 Surveillance of Antimicrobial Resistance among Bacterial Pathogens Isolated from Hospitalized Patients at

More information

crossm Global Assessment of the Activity of Tigecycline against Multidrug-Resistant Gram-negative pathogens between

crossm Global Assessment of the Activity of Tigecycline against Multidrug-Resistant Gram-negative pathogens between RESEARCH ARTICLE Clinical Science and Epidemiology crossm Global Assessment of the Activity of Tigecycline against Multidrug-Resistant Gram-Negative Pathogens between 2004 and 2014 as Part of the Tigecycline

More information

MICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC

MICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical

More information

Mechanism of antibiotic resistance

Mechanism of antibiotic resistance Mechanism of antibiotic resistance Dr.Siriwoot Sookkhee Ph.D (Biopharmaceutics) Department of Microbiology Faculty of Medicine, Chiang Mai University Antibiotic resistance Cross-resistance : resistance

More information

ESCMID Online Lecture Library. by author

ESCMID Online Lecture Library. by author Expert rules in susceptibility testing EUCAST-ESGARS-EPASG Educational Workshop Linz, 16 19 September, 2014 Dr. Rafael Cantón Hospital Universitario Ramón y Cajal SERVICIO DE MICROBIOLOGÍA Y PARASITOLOGÍA

More information

INCIDENCE OF BACTERIAL COLONISATION IN HOSPITALISED PATIENTS WITH DRUG-RESISTANT TUBERCULOSIS

INCIDENCE OF BACTERIAL COLONISATION IN HOSPITALISED PATIENTS WITH DRUG-RESISTANT TUBERCULOSIS INCIDENCE OF BACTERIAL COLONISATION IN HOSPITALISED PATIENTS WITH DRUG-RESISTANT TUBERCULOSIS 1 Research Associate, Drug Utilisation Research Unit, Nelson Mandela University 2 Human Sciences Research Council,

More information

GENERAL NOTES: 2016 site of infection type of organism location of the patient

GENERAL NOTES: 2016 site of infection type of organism location of the patient GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered

More information

EARS Net Report, Quarter

EARS Net Report, Quarter EARS Net Report, Quarter 4 213 March 214 Key Points for 213* Escherichia coli: The proportion of patients with invasive infections caused by E. coli producing extended spectrum β lactamases (ESBLs) increased

More information

Concise Antibiogram Toolkit Background

Concise Antibiogram Toolkit Background Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions

More information

Antimicrobial Stewardship Strategy: Antibiograms

Antimicrobial Stewardship Strategy: Antibiograms Antimicrobial Stewardship Strategy: Antibiograms A summary of the cumulative susceptibility of bacterial isolates to formulary antibiotics in a given institution or region. Its main functions are to guide

More information

Lianxin Liu 1* and Yuxing Ni 2*

Lianxin Liu 1* and Yuxing Ni 2* Liu and Ni BMC Infectious Diseases (2018) 18:584 https://doi.org/10.1186/s12879-018-3494-x RESEARCH ARTICLE Open Access Antimicrobial susceptibilities of specific syndromes created with organ-specific

More information

APPENDIX III - DOUBLE DISK TEST FOR ESBL

APPENDIX III - DOUBLE DISK TEST FOR ESBL Policy # MI\ANTI\04\03\v03 Page 1 of 5 Section: Antimicrobial Susceptibility Testing Manual Subject Title: Appendix III - Double Disk Test for ESBL Issued by: LABORATORY MANAGER Original Date: January

More information

Detecting / Reporting Resistance in Nonfastidious GNR Part #2. Janet A. Hindler, MCLS MT(ASCP)

Detecting / Reporting Resistance in Nonfastidious GNR Part #2. Janet A. Hindler, MCLS MT(ASCP) Detecting / Reporting Resistance in Nonfastidious GNR Part #2 Janet A. Hindler, MCLS MT(ASCP) Methods Described in CLSI M100-S21 for Testing non-enterobacteriaceae Organism Disk Diffusion MIC P. aeruginosa

More information

Prevalence of Extended Spectrum Beta- Lactamase Producers among Various Clinical Samples in a Tertiary Care Hospital: Kurnool District, India

Prevalence of Extended Spectrum Beta- Lactamase Producers among Various Clinical Samples in a Tertiary Care Hospital: Kurnool District, India International Journal of Current Microbiology and Applied Sciences ISSN: 319-77 Volume Number (17) pp. 57-3 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/1.5/ijcmas.17..31

More information

Nosocomial Infections: What Are the Unmet Needs

Nosocomial Infections: What Are the Unmet Needs Nosocomial Infections: What Are the Unmet Needs Jean Chastre, MD Service de Réanimation Médicale Hôpital Pitié-Salpêtrière, AP-HP, Université Pierre et Marie Curie, Paris 6, France www.reamedpitie.com

More information

Helen Heffernan. Rosemary Woodhouse

Helen Heffernan. Rosemary Woodhouse ANTIMICROBIAL RESISTANCE AMONG GRAM-NEGATIVE BACILLI FROM BACTERAEMIA, 2007 Helen Heffernan Rosemary Woodhouse Antibiotic Reference Laboratory Communicable Disease Group Institute of Environmental Science

More information

Fluoroquinolone Resistance Among Gram-Negative Urinary Tract Pathogens: Global Smart Program Results,

Fluoroquinolone Resistance Among Gram-Negative Urinary Tract Pathogens: Global Smart Program Results, 74 The Open Microbiology Journal, 2012, 6, 74-78 Open Access Fluoroquinolone Resistance Among Gram-Negative Urinary Tract Pathogens: Global Smart Program Results, 2009-2010 Sam Bouchillon 1*, Daryl J.

More information

Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory

Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory METHODS USED IN NEW ZEALAND DIAGNOSTIC LABORATORIES TO IDENTIFY AND REPORT EXTENDED-SPECTRUM β-lactamase- PRODUCING ENTEROBACTERIACEAE by Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory

More information

A retrospective analysis of urine culture results issued by the microbiology department, Teaching Hospital, Karapitiya

A retrospective analysis of urine culture results issued by the microbiology department, Teaching Hospital, Karapitiya A retrospective analysis of urine culture results issued by the microbiology department, Teaching Hospital, Karapitiya LU Edirisinghe 1, D Vidanagama 2 1 Senior Registrar in Medicine, 2 Consultant Microbiologist,

More information

Drug resistance analysis of bacterial strains isolated from burn patients

Drug resistance analysis of bacterial strains isolated from burn patients Drug resistance analysis of bacterial strains isolated from burn patients L.F. Wang, J.L. Li, W.H. Ma and J.Y. Li Inner Mongolia Institute of Burn Research, The Third Affiliated Hospital of Inner Mongolia

More information

Detection of Inducible AmpC β-lactamase-producing Gram-Negative Bacteria in a Teaching Tertiary Care Hospital in North India

Detection of Inducible AmpC β-lactamase-producing Gram-Negative Bacteria in a Teaching Tertiary Care Hospital in North India Original Article Vol. 25 No. 3 Ampc β-lactamase Production in Gram-Negative Bacilli:-Chaudhary U, et al. 129 Detection of Inducible AmpC β-lactamase-producing Gram-Negative Bacteria in a Teaching Tertiary

More information

What does multiresistance actually mean? Yohei Doi, MD, PhD University of Pittsburgh

What does multiresistance actually mean? Yohei Doi, MD, PhD University of Pittsburgh What does multiresistance actually mean? Yohei Doi, MD, PhD University of Pittsburgh Disclosures Merck Research grant Clinical context of multiresistance Resistance to more classes of agents Less options

More information

Activity of a novel aminoglycoside, ACHN-490, against clinical isolates of Escherichia coli and Klebsiella pneumoniae from New York City

Activity of a novel aminoglycoside, ACHN-490, against clinical isolates of Escherichia coli and Klebsiella pneumoniae from New York City Journal of Antimicrobial Chemotherapy Advance Access published July 31, 2010 J Antimicrob Chemother doi:10.1093/jac/dkq278 Activity of a novel aminoglycoside, ACHN-490, against clinical isolates of Escherichia

More information

2016 Antibiotic Susceptibility Report

2016 Antibiotic Susceptibility Report Fairview Northland Medical Center and Elk River, Milaca, Princeton and Zimmerman Clinics 2016 Antibiotic Susceptibility Report GRAM-NEGATIVE ORGANISMS 2016 Gram-Negative Non-Urine The number of isolates

More information

2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose

2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose 2017 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility

More information

Antibiotic Reference Laboratory, Institute of Environmental Science and Research Limited (ESR); August 2017

Antibiotic Reference Laboratory, Institute of Environmental Science and Research Limited (ESR); August 2017 Antimicrobial susceptibility of Shigella, 2015 and 2016 Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory, Institute of Environmental Science and Research Limited (ESR); August 2017

More information

PROTOCOL for serotyping and antimicrobial susceptibility testing of Salmonella test strains

PROTOCOL for serotyping and antimicrobial susceptibility testing of Salmonella test strains PROTOCOL for serotyping and antimicrobial susceptibility testing of Salmonella test strains 1 INTRODUCTION... 1 2 OBJECTIVES... 2 3 OUTLINE OF THE EQAS 2017... 2 3.1 Shipping, receipt and storage of strains...

More information

2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services

2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services 2015 Antibiogram Red Deer Regional Hospital Central Zone Alberta Health Services Introduction. This antibiogram is a cumulative report of the antimicrobial susceptibility rates of common microbial pathogens

More information

Detection of ESBL Producing Gram Negative Uropathogens and their Antibiotic Resistance Pattern from a Tertiary Care Centre, Bengaluru, India

Detection of ESBL Producing Gram Negative Uropathogens and their Antibiotic Resistance Pattern from a Tertiary Care Centre, Bengaluru, India ISSN: 2319-7706 Volume 4 Number 12 (2015) pp. 578-583 http://www.ijcmas.com Original Research Article Detection of ESBL Producing Gram Negative Uropathogens and their Antibiotic Resistance Pattern from

More information

Prevalence of Extended-spectrum β-lactamase Producing Enterobacteriaceae Strains in Latvia

Prevalence of Extended-spectrum β-lactamase Producing Enterobacteriaceae Strains in Latvia Prevalence of Extended-spectrum β-lactamase Producing Enterobacteriaceae Strains in Latvia Ruta Paberza 1, Solvita Selderiņa 1, Sandra Leja 1, Jelena Storoženko 1, Lilija Lužbinska 1, Aija Žileviča 2*

More information

Bacterial Pathogens in Urinary Tract Infection and Antibiotic Susceptibility Pattern from a Teaching Hospital, Bengaluru, India

Bacterial Pathogens in Urinary Tract Infection and Antibiotic Susceptibility Pattern from a Teaching Hospital, Bengaluru, India ISSN: 2319-7706 Volume 4 Number 11 (2015) pp. 731-736 http://www.ijcmas.com Original Research Article Bacterial Pathogens in Urinary Tract Infection and Antibiotic Susceptibility Pattern from a Teaching

More information

2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose

2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose 2016 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility

More information

BACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016)

BACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016) BACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016) VA Palo Alto Health Care System April 14, 2017 Trisha Nakasone, PharmD, Pharmacy Service Russell Ryono, PharmD, Public Health Surveillance

More information

Antibiotic utilization and Pseudomonas aeruginosa resistance in intensive care units

Antibiotic utilization and Pseudomonas aeruginosa resistance in intensive care units NEW MICROBIOLOGICA, 34, 291-298, 2011 Antibiotic utilization and Pseudomonas aeruginosa resistance in intensive care units Vladimíra Vojtová 1, Milan Kolář 2, Kristýna Hricová 2, Radek Uvízl 3, Jan Neiser

More information

An evaluation of the susceptibility patterns of Gram-negative organisms isolated in cancer centres with aminoglycoside usage

An evaluation of the susceptibility patterns of Gram-negative organisms isolated in cancer centres with aminoglycoside usage Journal of Antimicrobial Chemotherapy (1991) 27, Suppl. C, 1-7 An evaluation of the susceptibility patterns of Gram-negative organisms isolated in cancer centres with aminoglycoside usage J. J. Muscato",

More information

National Surveillance of Antimicrobial Resistance in Pseudomonas aeruginosa Isolates Obtained from Intensive Care Unit Patients from 1993 to 2002

National Surveillance of Antimicrobial Resistance in Pseudomonas aeruginosa Isolates Obtained from Intensive Care Unit Patients from 1993 to 2002 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Dec. 2004, p. 4606 4610 Vol. 48, No. 12 0066-4804/04/$08.00 0 DOI: 10.1128/AAC.48.12.4606 4610.2004 Copyright 2004, American Society for Microbiology. All Rights

More information

Original Articles. K A M S W Gunarathne 1, M Akbar 2, K Karunarathne 3, JRS de Silva 4. Sri Lanka Journal of Child Health, 2011; 40(4):

Original Articles. K A M S W Gunarathne 1, M Akbar 2, K Karunarathne 3, JRS de Silva 4. Sri Lanka Journal of Child Health, 2011; 40(4): Original Articles Analysis of blood/tracheal culture results to assess common pathogens and pattern of antibiotic resistance at medical intensive care unit, Lady Ridgeway Hospital for Children K A M S

More information

Aerobic bacterial infections in a burns unit of Sassoon General Hospital, Pune

Aerobic bacterial infections in a burns unit of Sassoon General Hospital, Pune Original article Aerobic bacterial infections in a burns unit of Sassoon General Hospital, Pune Patil P, Joshi S, Bharadwaj R. Department of Microbiology, B.J. Medical College, Pune, India. Corresponding

More information

CONTAGIOUS COMMENTS Department of Epidemiology

CONTAGIOUS COMMENTS Department of Epidemiology VOLUME XXIII NUMBER 1 July 2008 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell, SM (ASCP), Marti Roe SM (ASCP), Ann-Christine Nyquist MD, MSPH Are the bugs winning? The 2007

More information

PrevalenceofAntimicrobialResistanceamongGramNegativeIsolatesinanAdultIntensiveCareUnitataTertiaryCareCenterinSaudiArabia

PrevalenceofAntimicrobialResistanceamongGramNegativeIsolatesinanAdultIntensiveCareUnitataTertiaryCareCenterinSaudiArabia : K Interdisciplinary Volume 17 Issue 4 Version 1.0 Year 2017 Type: Double Blind Peer Reviewed International Research Journal Publisher: Global Journals Inc. (USA) Online ISSN: 2249-4618 & Print ISSN:

More information

Multi-drug resistant Acinetobacter (MDRA) Surveillance and Control. Alison Holmes

Multi-drug resistant Acinetobacter (MDRA) Surveillance and Control. Alison Holmes Multi-drug resistant Acinetobacter (MDRA) Surveillance and Control Alison Holmes The organism and it s epidemiology Surveillance Control What is it? What is it? What is it? What is it? Acinetobacter :

More information

Understanding the Hospital Antibiogram

Understanding the Hospital Antibiogram Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital

More information

Research, National Health Research Institute, Zhunan, Taiwan. Received: May 1, 2008 Revised: June 4, 2008 Accepted: July 4, 2008

Research, National Health Research Institute, Zhunan, Taiwan. Received: May 1, 2008 Revised: June 4, 2008 Accepted: July 4, 2008 J Microbiol Immunol Infect. 2009;42:310-316 Prevalence of extended-spectrum β-lactamases in Enterobacter cloacae in Taiwan and comparison of 3 phenotypic confirmatory methods for detecting extended-spectrum

More information

Comparative Assessment of b-lactamases Produced by Multidrug Resistant Bacteria

Comparative Assessment of b-lactamases Produced by Multidrug Resistant Bacteria Comparative Assessment of b-lactamases Produced by Multidrug Resistant Bacteria Juhee Ahn Department of Medical Biomaterials Engineering Kangwon National University October 23, 27 Antibiotic Development

More information

Outline. Antimicrobial resistance. Antimicrobial resistance in gram negative bacilli. % susceptibility 7/11/2010

Outline. Antimicrobial resistance. Antimicrobial resistance in gram negative bacilli. % susceptibility 7/11/2010 Multi-Drug Resistant Organisms Is Combination Therapy the Way to Go? Sutthiporn Pattharachayakul, PharmD Prince of Songkhla University, Thailand Outline Prevalence of anti-microbial resistance in Acinetobacter

More information

Pharmacokinetic-pharmacodynamic profiling of four antimicrobials against Gram-negative bacteria collected from Shenyang, China

Pharmacokinetic-pharmacodynamic profiling of four antimicrobials against Gram-negative bacteria collected from Shenyang, China RESEARCH ARTICLE Open Access Research article Pharmacokinetic-pharmacodynamic profiling of four antimicrobials against Gram-negative bacteria collected from Shenyang, China Yun Zhuo Chu 1, Su Fei Tian

More information

a. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2.

a. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2. AND QUANTITATIVE PRECISION (SAMPLE UR-01, 2017) Background and Plan of Analysis Sample UR-01 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony

More information

The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards

The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards Janet A. Hindler, MCLS, MT(ASCP) UCLA Health System Los Angeles, California, USA jhindler@ucla.edu 1 Learning Objectives Describe information

More information

Appropriate antimicrobial therapy in HAP: What does this mean?

Appropriate antimicrobial therapy in HAP: What does this mean? Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,

More information

Overnight identification of imipenem-resistant Acinetobacter baumannii carriage in hospitalized patients

Overnight identification of imipenem-resistant Acinetobacter baumannii carriage in hospitalized patients TABLE 1. Origin and carbapenem resistance characteristics of the 64 Acinetobacter baumannii stock D-750 Overnight identification of imipenem-resistant Acinetobacter baumannii carriage in hospitalized patients

More information

Other β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL

Other β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL Other β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL David P. Nicolau, PharmD, FCCP, FIDSA Director, Center for Anti-Infective Research and Development Hartford Hospital

More information

RESEARCH ARTICLE ANTIBIOGRAM

RESEARCH ARTICLE ANTIBIOGRAM RESEARCH ARTICLE ANTIBIOGRAM OF ESCHERICHIA COLI, KLEBSIELLA PNEUMONIAE, AND KLEBSIELLA OXYTOCA FROM INVASIVE DISEASE CASES AT A TERTIARY CARE UNIVERSITY HOSPITAL IN THE CENTRAL REGION OF JAPAN FROM 2008

More information

Original Article. Suthan Srisangkaew, M.D. Malai Vorachit, D.Sc.

Original Article. Suthan Srisangkaew, M.D. Malai Vorachit, D.Sc. Original Article Vol. 21 No.1 The optimum agent for ESBL screening and confirmatory tests:- Srisangkaew S & Vorachit M. 1 The Optimum Agent for Screening and Confirmatory Tests for Extended-Spectrum Beta-Lactamases

More information

MDR Acinetobacter baumannii. Has the post antibiotic era arrived? Dr. Michael A. Borg Infection Control Dept Mater Dei Hospital Malta

MDR Acinetobacter baumannii. Has the post antibiotic era arrived? Dr. Michael A. Borg Infection Control Dept Mater Dei Hospital Malta MDR Acinetobacter baumannii Has the post antibiotic era arrived? Dr. Michael A. Borg Infection Control Dept Mater Dei Hospital Malta 1 The Armageddon recipe Transmissible organism with prolonged environmental

More information

β-lactams resistance among Enterobacteriaceae in Morocco 1 st ICREID Addis Ababa March 2018

β-lactams resistance among Enterobacteriaceae in Morocco 1 st ICREID Addis Ababa March 2018 β-lactams resistance among Enterobacteriaceae in Morocco 1 st ICREID Addis Ababa 12-14 March 2018 Antibiotic resistance center Institut Pasteur du Maroc Enterobacteriaceae (E. coli, Salmonella, ) S. aureus

More information

2015 Antibiotic Susceptibility Report

2015 Antibiotic Susceptibility Report Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus influenzenza Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens

More information

ORIGINAL ARTICLE ABSTRACT

ORIGINAL ARTICLE ABSTRACT ORIGINAL ARTICLE Increasing prevalence of extended-spectrum-betalactamase among Gram-negative bacilli in Latin America 28 update from the Study for Monitoring Antimicrobial Resistance Trends (SMART) Authors

More information

Witchcraft for Gram negatives

Witchcraft for Gram negatives Witchcraft for Gram negatives Dr Subramanian S MD DNB MNAMS AB (Medicine, Infect Dis) Infectious Diseases Consultant Global Health City, Chennai www.asksubra.com Drug resistance follows the drug like a

More information

Zhang et al. BMC Infectious Diseases (2017) 17:776 DOI /s z

Zhang et al. BMC Infectious Diseases (2017) 17:776 DOI /s z Zhang et al. BMC Infectious Diseases (2017) 17:776 DOI 10.1186/s12879-017-2873-z RESEARCH ARTICLE Open Access Update of incidence and antimicrobial susceptibility trends of Escherichia coli and Klebsiella

More information

Available online at

Available online at Available online at www.annclinlabsci.org Time-Kill Synergy Tests of Tigecycline Combined with Imipenem, Amikacin, and Ciprofloxacin against Clinical Isolates of Multidrug-Resistant Klebsiella pneumoniae

More information

Safe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times

Safe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times Safe Patient Care Keeping our Residents Safe 2016 Use Standard Precautions for ALL Residents at ALL times #safepatientcare Do bugs need drugs? Dr Deirdre O Brien Consultant Microbiologist Mercy University

More information

Successful stewardship in hospital settings

Successful stewardship in hospital settings Successful stewardship in hospital settings Pr Charles-Edouard Luyt Service de Réanimation Institut de Cardiologie Groupe Hospitalier Pitié-Salpêtrière Université Pierre et Marie Curie, Paris 6 www.reamedpitie.com

More information

Antimicrobial Susceptibility Patterns

Antimicrobial Susceptibility Patterns Antimicrobial Susceptibility Patterns KNH SURGERY Department Masika M.M. Department of Medical Microbiology, UoN Medicines & Therapeutics Committee, KNH Outline Methodology Overall KNH data Surgery department

More information

Fighting MDR Pathogens in the ICU

Fighting MDR Pathogens in the ICU Fighting MDR Pathogens in the ICU Dr. Murat Akova Hacettepe University School of Medicine, Department of Infectious Diseases, Ankara, Turkey 1 50.000 deaths each year in US and Europe due to antimicrobial

More information

Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing

Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing These suggestions are intended to indicate minimum sets of agents to test routinely in a diagnostic laboratory

More information

Version 1.01 (01/10/2016)

Version 1.01 (01/10/2016) CHN58: ANTIMICROBIAL SUSCEPTIBILITY TESTING (CLSI) 1.0 PURPOSE / INTRODUCTION: 1.1 Introduction Antimicrobial susceptibility tests are performed in order to determine whether a pathogen is likely to be

More information

Annual Report: Table 1. Antimicrobial Susceptibility Results for 2,488 Isolates of S. pneumoniae Collected Nationally, 2005 MIC (µg/ml)

Annual Report: Table 1. Antimicrobial Susceptibility Results for 2,488 Isolates of S. pneumoniae Collected Nationally, 2005 MIC (µg/ml) Streptococcus pneumoniae Annual Report: 5 In 5, a total of, isolates of pneumococci were collected from 59 clinical microbiology laboratories across Canada. Of these, 733 (9.5%) were isolated from blood

More information

International Journal of Health Sciences and Research ISSN:

International Journal of Health Sciences and Research  ISSN: International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Antibiotic Susceptibility Pattern of Pseudomonas Aeruginosa Isolated From Various Clinical

More information

THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS

THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS Stefanie Desmet University Hospitals Leuven Laboratory medicine microbiology stefanie.desmet@uzleuven.be

More information

2010 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Children s Hospital

2010 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Children s Hospital 2010 ANTIBIOGRAM University of Alberta Hospital and the Stollery Children s Hospital Medical Microbiology Department of Laboratory Medicine and Pathology Table of Contents Page Introduction..... 2 Antibiogram

More information

Multidrug-Resistant Organisms: How Do We Define them? How do We Stop Them?

Multidrug-Resistant Organisms: How Do We Define them? How do We Stop Them? Multidrug-Resistant Organisms: How Do We Define them? How do We Stop Them? Roberta B. Carey, PhD Centers for Disease Control and Prevention Division of Healthcare Quality Promotion Why worry? MDROs Clinical

More information

International Journal of Antimicrobial Agents 28 (2006)

International Journal of Antimicrobial Agents 28 (2006) International Journal of Antimicrobial Agents 28 (2006) 532 536 Activity of tigecycline against clinical isolates of Staphylococcus aureus and extended-spectrum -lactamase-producing Escherichia coli in

More information

Acinetobacter lwoffii h h

Acinetobacter lwoffii h h hh Acinetobacter lwoffii h h h h hh MBL Acinetobacter lwoffii MBL A. lwoffii MBL MBL Acinetobacter lwoffii hh Staphylococcus pseudintermedius Pseudomonas aeruginosa h Escherichia coli, hhh ABCD Ambler

More information

Comparison of Susceptibility of Gram Negative Bacilli to Cephalosporins and Ciprofloxacin

Comparison of Susceptibility of Gram Negative Bacilli to Cephalosporins and Ciprofloxacin International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 5 Number 9 (2016) pp. 205-212 Journal homepage: http://www.ijcmas.com Original Research Article http://dx.doi.org/10.20546/ijcmas.2016.509.023

More information

Research on pathogenic bacteria and antibiotic resistance of Enterobacteriaceae in hospitalized elderly patients.

Research on pathogenic bacteria and antibiotic resistance of Enterobacteriaceae in hospitalized elderly patients. Biomedical Research 2017; 28 (16): 7243-7247 ISSN 0970-938X www.biomedres.info Research on pathogenic bacteria and antibiotic resistance of Enterobacteriaceae in hospitalized elderly patients. Feng Zheng

More information

Protocol for Surveillance of Antimicrobial Resistance in Urinary Isolates in Scotland

Protocol for Surveillance of Antimicrobial Resistance in Urinary Isolates in Scotland Protocol for Surveillance of Antimicrobial Resistance in Urinary Isolates in Scotland Version 1.0 23 December 2011 General enquiries and contact details This is the first version (1.0) of the Protocol

More information